NYSE:FNA

Paragon 28 (FNA) Stock Price, News & Analysis

$8.80
-0.17 (-1.90%)
(As of 04:10 PM ET)
Today's Range
$8.73
$9.18
50-Day Range
$8.87
$13.94
52-Week Range
$7.95
$19.72
Volume
554,071 shs
Average Volume
527,643 shs
Market Capitalization
$729.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Paragon 28 MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.8% Upside
$17.67 Price Target
Short Interest
Bearish
9.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.33mentions of Paragon 28 in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$255,360 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

633rd out of 908 stocks

Medical Devices Industry

1st out of 2 stocks

FNA stock logo

About Paragon 28 Stock (NYSE:FNA)

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

FNA Stock Price History

FNA Stock News Headlines

Protect Yourself While There’s Still Time …
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
Unveiling 4 Analyst Insights On Paragon 28
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Piper Sandler Keeps Their Buy Rating on Paragon 28 (FNA)
Q4 2023 Paragon 28 Inc Earnings Call
Recap: Paragon 28 Q4 Earnings
Earnings Outlook For Paragon 28
See More Headlines
Receive FNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paragon 28 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/26/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Fax
N/A
Employees
574
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.67
High Stock Price Target
$18.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+101.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-47,840,000.00
Pretax Margin
-22.01%

Debt

Sales & Book Value

Annual Sales
$216.39 million
Book Value
$2.15 per share

Miscellaneous

Free Float
70,205,000
Market Cap
$728.78 million
Optionable
Optionable
Beta
1.01
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Albert DaCostaMr. Albert DaCosta (Age 50)
    Co-Founder, Chairman, President & CEO
    Comp: $1.4M
  • Ms. Kristina Wright (Age 47)
    Independent Interim CFO & Director
    Comp: $70k
  • Mr. Robert S. McCormack J.D. (Age 56)
    General Counsel & Secretary
    Comp: $477.53k
  • Mr. Matthew Jarboe (Age 40)
    Chief Commercial Officer
    Comp: $899.92k
  • Mr. Andrew James Hill (Age 40)
    Executive Vice President of Research & Development
    Comp: $306.06k
  • Mr. Jeff Sears
    Vice President of Operations
  • Mr. Erik E Mickelson (Age 42)
    Chief Accounting Officer & Controller
  • Matt Brinckman
    Senior Vice President of Strategy & Investor Relations
  • Ms. Michelle Missal
    VP & Chief Compliance Officer
  • Mr. John Shumaker
    Executive Vice President of Sales - U.S.

FNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Paragon 28 stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paragon 28 in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FNA shares.
View FNA analyst ratings
or view top-rated stocks.

What is Paragon 28's stock price target for 2024?

4 Wall Street analysts have issued twelve-month price objectives for Paragon 28's shares. Their FNA share price targets range from $17.00 to $18.00. On average, they predict the company's stock price to reach $17.67 in the next year. This suggests a possible upside of 100.8% from the stock's current price.
View analysts price targets for FNA
or view top-rated stocks among Wall Street analysts.

How have FNA shares performed in 2024?

Paragon 28's stock was trading at $12.43 at the beginning of 2024. Since then, FNA shares have decreased by 29.2% and is now trading at $8.80.
View the best growth stocks for 2024 here
.

Are investors shorting Paragon 28?

Paragon 28 saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,410,000 shares, an increase of 40.3% from the March 31st total of 2,430,000 shares. Based on an average trading volume of 517,400 shares, the days-to-cover ratio is presently 6.6 days. Approximately 9.3% of the shares of the company are short sold.
View Paragon 28's Short Interest
.

When is Paragon 28's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our FNA earnings forecast
.

How were Paragon 28's earnings last quarter?

Paragon 28, Inc. (NYSE:FNA) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.09. The company earned $60.56 million during the quarter, compared to analyst estimates of $60.73 million. Paragon 28 had a negative net margin of 22.11% and a negative trailing twelve-month return on equity of 22.51%.

What guidance has Paragon 28 issued on next quarter's earnings?

Paragon 28 issued an update on its FY 2024 earnings guidance on Friday, April, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $249.0 million-$259.0 million, compared to the consensus revenue estimate of $253.9 million.

When did Paragon 28 IPO?

Paragon 28 (FNA) raised $125 million in an IPO on Friday, October 15th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. BofA Securities and Piper Sandler served as the underwriters for the IPO and Canaccord Genuity, JMP Securities and Needham & Company were co-managers.

How do I buy shares of Paragon 28?

Shares of FNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:FNA) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners